
Pasirinkite etiketę
rodoma tiesiai ant flakonoReta + Cagri Blend
GLP-1
- Siunčiame iš Vokietijos
Užsakymas
- DHL su sekimu
- Diskreti pakuotė
Trumpai
Reta + Cagri Blend skaičiais
Pagrindiniai rodikliai iš mūsų žinyno.
Visas žinyno įrašas- Class
- Triple agonistGLP-1 / GIP / glucagon, + amylin analog
- Half-life
- Retatrutide around 6 dayscagrilintide around 7 to 8 days
- Form
- Lyophilisatepowder, reconstituted with BAC water
- Sizes
- 30 mg1 size in the shop
What studies show
All 5 sources in the lexicon- up to24.2 %Jastreboff et al., NEJM, 2023
- Sanyal et al., Nature Medicine, 2024
- Lau et al., The Lancet, 2021
Atsiliepimai
Ką sako klientai
Tik tikri užsakymai, kuriuose buvo Reta + Cagri Blend.
Visi atsiliepimaiProduktui Reta + Cagri Blend laboratorinės analizės dar nėra. Balsuoti už taiUžsakykite tyrimą, mes apmokame pusęVisos laboratorinės analizės
Žinios
Viskas apie Reta + Cagri Blend
Išsami informacija netrukus.
Dozavimas
Įkeliama dozavimo informacija …
Pravers
Ko dar jums reikės
Bakteriostatinis vanduo į krepšelį pridedamas automatiškai. Švirkštai ir servetėlės - vienu paspaudimu.
Insulino švirkštai
10 vnt. · 5.50 €
Spiritinės servetėlės
50 vnt. · 10 €
Kiek vandens?
Vienetai ant švirkšto jūsų flakono dydžiui.
Atidaryti skaičiuoklę →Is the Reta + Cagri Blend approved or studied?
No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and cagrilintide together. Both components are in phase 3 and not approved.
Why Retatrutide and cagrilintide together?
Both act on different satiety pathways: Retatrutide on GLP-1, GIP and glucagon, cagrilintide on amylin receptors. With semaglutide as the partner, weight loss in a phase 1b trial after 20 weeks was 17.1 instead of 9.8 percent. For Retatrutide as the partner there are no data.
What do the studies of the components show?
Retatrutide alone: in TRIUMPH-1 after 80 weeks 25.0 percent less body weight on average at the highest study dose, 3.9 percent on placebo. Cagrilintide alone: up to 10.8 percent after 26 weeks in phase 2, 3.0 percent on placebo. In a substudy liver fat also fell sharply on Retatrutide.
Why is the cagrilintide share so small?
The vial contains five times as much Retatrutide as cagrilintide, because Retatrutide is the stronger and limiting part. Anyone going by the Retatrutide share stays far below the amounts used in the cagrilintide trials. Whether the small share contributes anything has not been studied.
How long do the components stay in the body?
Retatrutide had a half-life of about six days in a phase 1b study, cagrilintide 159 to 195 hours in another study, so about a week. Both fit one dose per week.
Which side effects were seen with the components?
With both, mainly gastrointestinal effects such as nausea and diarrhoea, depending on the dose. On Retatrutide heart rate rose in a dose-dependent way in phase 2. Two satiety signals together may strengthen nausea at the start, this has not been measured for this blend.
Which trials are still running?
Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The RENEW trials of cagrilintide alone run until 2027. No trial of the blend is listed in the registry.
Susiję
Susiję produktai
Tirzepatide
Peptidai · GLP-1 ir riebalų mažinimas GLP-1 ir riebalų mažinimas
Dydžių: 10
Patikrinta laboratorijoje
= nuo 10 €/flakonas
Retatrutide
Peptidai · GLP-1 ir riebalų mažinimas GLP-1 ir riebalų mažinimas
Dydžių: 11
Patikrinta laboratorijoje
= nuo 16 €/flakonas
Semaglutide
Peptidai · GLP-1 ir riebalų mažinimas GLP-1 ir riebalų mažinimas
Dydžių: 6
Patikrinta laboratorijoje
= nuo 10 €/flakonas
Mazdutide
Peptidai · GLP-1 ir riebalų mažinimas GLP-1 ir riebalų mažinimas
Dydžių: 2
= nuo 32 €/flakonas
Reta + Cagri Blend